Abstract 15377: Stabilization of Cardiac Function in Wild-Type Transthyretin Cardiac Amyloidosis With Diflunisal
Graham Lohrmann(Boston University), Frederick L. Ruberg(Boston University), Roberta Mussinelli, Lawreen H. Connors(Boston University), Deepa M. Gopal(Boston University), Nirupama Vellanki(Boston University), Jennifer Hellawell(Amgen (United States)), Omar K. Siddiqi(Boston University), Alexandra Pipilas(Boston University), Jonathan C. Fox(Fluidigm (United States)), John L. Berk(Boston University)
Circulation
November 6, 2018
Cited by 0
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy
|Circulation|2018|837